Compare Crescent Energy Company Class A Common Stock (CRGY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Merck & Co., Inc. — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.81 (market cap $4.30B), while Merck & Co., Inc. trades at $145.74 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 81.7× Crescent Energy Company Class A Common Stock's market cap, and Crescent Energy Company Class A Common Stock pays the higher dividend (3.69%). Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.
| CRGY | MRK | |
|---|---|---|
Market Cap | $4.30B | $351.28B |
Volume | 15,201,625 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $15.37 | $156.43 |
52-Week Low | $7.75 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $9.31B | $398.04B |
Dividend Yield | 3.69% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
